Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, today announced the commercial launch of its new gene expression test for prostate cancer. This new test will be available through Clarient’s PATHSiTETM virtual reporting tool and accessible to the company’s entire pathology network Clarient’s […]

Evogen, Inc., a global molecular diagnostics company, and LGC, an international science-based company and recognised provider of laboratory services and measurement standards, announced today that they have signed a worldwide license agreement of LGC’s HyBeacons® PCR probe chemistry technology to Evogen to augment the recently launched rapid molecular diagnostics and detection platform, including the flagship […]

Perlegen, a leader in correlating genetic variation to predisposition to disease and drug response through development of genetic tests, announced today that it has hired Mark J. Ostrowski as senior vice president of sales. In this newly created position, Mr. Ostrowski will bring his deep experience with Perlegen’s commercial targets to reach and expand the […]

MARLBOROUGH, Mass.–EXACT Sciences Corporation (NASDAQ: EXAS) announced that its Board of Directors has unanimously rejected an acquisition proposal by Sequenom, Inc. (NASDAQ: SQNM) to acquire EXACT for $1.50 per share in Sequenom common stock, subject to a collar. The Board, after reviewing the proposal with its financial and legal advisors, has determined to reject the […]

VENLO, THE NETHERLANDS–Jan 12, 2009 — QIAGEN led-consortium to develop standards for patient sample processing in order to facilitate the discovery and prediction of diseases Venlo, The Netherlands, January 12, 2009 – The European Union launched a new research project targeting to expand the potentials and utility of in-vitro diagnostics through the creation of new […]